European Hematology Association Congress | Conference

Dr. Pieter Sonneveld on a Prognostic Indicator for Multiple Myeloma

July 5th 2016

Dr. Jorge Sierra on Risk Adapted Therapy in AML

June 23rd 2016

Inotuzumab Ozogamicin Improves Outcomes in Relapsed/Refractory ALL

June 13th 2016

Inotuzumab ozogamicin demonstrated significantly improved progression-free survival and complete remission rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia.

Long-Term COMFORT-I Data Confirm Ruxolitinib Survival Benefit

June 12th 2016

Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis.

Antibodies From Cured AML Patients Kill Leukemia Cells

June 12th 2016

Patients with acute myeloid leukemia who are cured after allogeneic hematopoietic stem cell transplantation produce antibodies that destroy leukemia cells.

Dr. Anas Younes on Impact of CheckMate 205 in Classical Hodgkin Lymphoma

June 12th 2016

Dr. Jakubowiak on Improved Efficacy with ASCT+ KRd in Multiple Myeloma

June 12th 2016

Daratumumab Triplet Reduces Risk of Progression by 63% in Myeloma

June 12th 2016

Combining the CD38-targeted antibody daratumumab with lenalidomide and dexamethasone reduced the risk of disease progression by 63% versus lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III POLLUX (MMY3003) trial.

Targeted Therapies Could Revolutionize AML Treatment

June 12th 2016

A host of novel agents that target distinct molecular targets are pushing complete remission rates beyond historical boundaries for patients with acute myeloid leukemia.

Vadastuximab Talirine, HMA Combo Induces Impressive Remissions in AML

June 12th 2016

Frontline treatment with the CD33-directed antibody-drug conjugate vadastuximab talirine plus a hypomethylating agent induced deep and durable remissions for older patients with acute myeloid leukemia.

Dr. Christian Gisselbrecht on Defining Refractory Disease in DLBCL

June 11th 2016

​Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).

Dr. Wojciech Jurczak on MOR208 in Non-Hodgkin's Lymphoma

June 11th 2016

​Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).

Stopping TKIs Proven Safe in Chronic Phase CML

June 11th 2016

Tyrosine kinase inhibitors can safely be halted in select patients with chronic phase chronic myeloid leukemia followed a maintained deep molecular remission.

Blinatumomab Nearly Doubles Survival in Acute Lymphoblastic Leukemia

June 11th 2016

The median overall survival with the anti-CD19 immunotherapy blinatumomab was 7.7 months versus 4 months with standard chemotherapy in patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to results from the phase III TOWER study.

Ibrutinib Highly Effective for Del17p CLL in Combined Analysis

June 11th 2016

Ibrutinib continued to demonstrate impressive antitumor activity in a pooled analysis of 243 patients with deletion 17p chronic lymphocytic leukemia.

Dr. Ruben Mesa on COMFORT-I for Myelofibrosis

June 10th 2016

Dr. Jae Park on Impact of Disease Burden on CAR T-Cells in Relapsed B-ALL

June 10th 2016